|
|
|
|
|
Last Trade
|
Last Trade:
$38.50
|
Change:
-1.45 (-3.63%)
|
Trade Time:
Jul 16
|
Market Cap:
$1.69B
|
|
|
|
|
|
|
Description of Business
|
|
Atara Biotherapeutics is a leading T-cell immunotherapy company developing novel
treatments for patients with cancer, autoimmune and viral diseases. The
Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors
with healthy immune function and allow for rapid delivery from inventory to
patients without a requirement for pretreatment. Atara's T-cell immunotherapies
are designed to precisely recognize and eliminate cancerous or diseased cells
without affecting normal, healthy cells. Atara's most advanced T-cell
immunotherapy in development, tabelecleucel (formerly known as ATA129), is being
developed for the treatment of patients with Epstein-Barr virus, or EBV,
associated post-transplant lymphoproliferative disorder, or EBV+ PTLD, who have
failed rituximab, as well as other EBV associated hematologic and solid tumors,
including nasopharyngeal carcinoma, or NPC.
|
|
|
|